➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Last Updated: July 30, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,012,462

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,012,462 protect, and when does it expire?

Patent 9,012,462 protects ALUNBRIG and is included in one NDA.

This patent has forty-five patent family members in twenty-four countries.

Summary for Patent: 9,012,462
Title:Phosphorous derivatives as kinase inhibitors
Abstract: The invention features compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use. ##STR00001##
Inventor(s): Wang; Yihan (Newton, MA), Huang; Wei-Sheng (Acton, MA), Liu; Shuangying (Wellesley, MA), Shakespeare; William C. (Southborough, MA), Thomas; R. Mathew (Sharon, MA), Qi; Jiwei (West Roxbury, MA), Li; Feng (Winchester, MA), Zhu; Xiaotian (Newton, MA), Kohlman; Anna (Winchester, MA), Dalgarno; David C. (Brookline, MA), Romero; Jan Antoinette C. (Somerville, MA), Zou; Dong (Concord, MA)
Assignee: Ariad Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:12/736,910
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 9,012,462

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa ALUNBRIG brigatinib TABLET;ORAL 208772-001 Apr 28, 2017 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Takeda Pharms Usa ALUNBRIG brigatinib TABLET;ORAL 208772-002 Apr 28, 2017 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Takeda Pharms Usa ALUNBRIG brigatinib TABLET;ORAL 208772-003 Oct 2, 2017 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,012,462

PCT Information
PCT FiledMay 21, 2009PCT Application Number:PCT/US2009/044918
PCT Publication Date:November 26, 2009PCT Publication Number: WO2009/143389

International Family Members for US Patent 9,012,462

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009248923 ⤷  Free Forever Trial
Brazil PI0908637 ⤷  Free Forever Trial
Canada 2723961 ⤷  Free Forever Trial
China 102105150 ⤷  Free Forever Trial
Cyprus 1119534 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.